News

Calla Lily wins £700,000 Innovate UK grant for microbiome device

What's the deal? Calla Lily Clinical CareDealroom has a profile for this one. Try Dealroom →, a clinical-stage women's health company, has won a £700,000 Innovate UK grant to adapt its Callavid device for delivering beneficial bacteria to restore vaginal microbiome health. The award, made through Innovate UK's Growth Catalyst: Investor Partnerships programme, pairs grant money with matched private investment and funds a £1 million project.

What's the endgame? The project, named FLORA, uses Callavid's intravaginal delivery platform to improve the transfer and retention of Lactobacillus species, which help maintain a healthy microbiome. Calla Lily aims to make Callavid the first over-the-counter product designed to maximise probiotic colonisation while overcoming leakage and dosing problems in existing formats.

Why now? Vaginal dysbiosis is linked to higher risk of infection, miscarriage, and preterm birth, yet treatment remains largely antibiotic-based. Bacterial vaginosis recurs in roughly 58% of women within 12 months, fuelling antimicrobial resistance.

What else? This is Calla Lily's third Innovate UK grant and the third application of the Callavid platform to secure independent funding, after progesterone work backed by the National Institute for Health and Care Research and antibiotic delivery under Wellcome LeapDealroom has a profile for this one. Try Dealroom →'s $50 million Focused Antibiotics programme.

What they said: "Innovate UK has backed us from our earliest days and helped us build Callavid capital-efficiently. This third award takes us into an entirely new area," said Thang Vo-Ta, co-founder and chief executive officer.

What could go wrong? This is an R&D award, not evidence that Callavid's microbiome application works. The company must still show its device improves bacterial retention and colonisation.

The signal: The grant sits within a growing push to test vaginal live biotherapeutics, including a UK trial of OselDealroom has a profile for this one. Try Dealroom →'s Lactin-V examining whether Lactobacillus crispatus can cut preterm birth risk. Alongside a February 2026 collaboration with Merck, the funding marks rising industry interest in the platform—though as non-dilutive R&D money, it signals confidence more than proof.

Read more: markets.financialcontent.com

Image credit: "20110420-RD-LSC-1073" by USDAgov, public domain (Public Domain Mark 1.0)

More top stories